31084994|t|Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.
31084994|a|OBJECTIVE: Studies have shown that antidepressants are no better than placebo in treating depression in dementia. The authors examined antidepressant efficacy in subgroups of depression in dementia with different depressive symptom profiles. METHODS: This study focuses on exploratory secondary analyses on the randomized, parallel-group, double-blind, placebo-controlled Health Technology Assessment Study of the Use of Antidepressants for Depression in Dementia (HTA-SADD) trial. The setting included old-age psychiatry services in nine centers in England. The participants included 326 patients meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association probable/possible Alzheimer disease criteria, and Cornell Scale for Depression in Dementia (CSDD) scores of 8 or more. Intervention was placebo (n = 111), sertraline (n = 107), or mirtazapine (n = 108). Latent class analyses (LCA) on baseline CSDD items clustered participants into symptom-based subgroups. Mixed-model analysis evaluated CSDD improvement at 13 and 39 weeks by randomization in each subgroup. RESULTS: LCA yielded 4 subgroups: severe (n = 34), psychological (n = 86), affective (n = 129), and somatic (n = 77). Mirtazapine, but not sertraline, outperformed placebo in the psychological subgroup at week 13 (adjusted estimate: -2.77 [standard error (SE) 1.16; 95% confidence interval: -5.09 to -0.46]), which remained, but lost statistical significance at week 39 (adjusted estimate: -2.97 [SE 1.59; 95% confidence interval: -6.15 to 0.20]). Neither sertraline nor mirtazapine outperformed placebo in the other subgroups. CONCLUSION: Because of the exploratory nature of the analyses and the small sample sizes for subgroup analysis there is the need for caution in interpreting these data. Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable. These data should not change clinical practice, but future trials should consider stratifying types of depression in dementia in secondary analyses.
31084994	0	10	Sertraline	Chemical	MESH:D020280
31084994	15	26	Mirtazapine	Chemical	MESH:D000078785
31084994	58	68	Depression	Disease	MESH:D003866
31084994	72	80	Dementia	Disease	MESH:D003704
31084994	100	103	HTA	Disease	
31084994	104	108	SADD	Disease	
31084994	228	238	depression	Disease	MESH:D003866
31084994	242	250	dementia	Disease	MESH:D003704
31084994	313	323	depression	Disease	MESH:D003866
31084994	327	335	dementia	Disease	MESH:D003704
31084994	351	369	depressive symptom	Disease	MESH:D003866
31084994	579	589	Depression	Disease	MESH:D003866
31084994	593	601	Dementia	Disease	MESH:D003704
31084994	603	606	HTA	Disease	
31084994	607	611	SADD	Disease	
31084994	727	735	patients	Species	9606
31084994	766	806	Neurological and Communicative Disorders	Disease	MESH:D003147
31084994	811	817	Stroke	Disease	MESH:D020521
31084994	818	837	Alzheimer's Disease	Disease	MESH:D000544
31084994	890	907	Alzheimer disease	Disease	MESH:D000544
31084994	940	950	Depression	Disease	MESH:D003866
31084994	954	962	Dementia	Disease	MESH:D003704
31084994	964	968	CSDD	Disease	MESH:C538175
31084994	1027	1037	sertraline	Chemical	MESH:D020280
31084994	1052	1063	mirtazapine	Chemical	MESH:D000078785
31084994	1115	1119	CSDD	Disease	MESH:C538175
31084994	1210	1214	CSDD	Disease	MESH:C538175
31084994	1399	1410	Mirtazapine	Chemical	MESH:D000078785
31084994	1420	1430	sertraline	Chemical	MESH:D020280
31084994	1737	1747	sertraline	Chemical	MESH:D020280
31084994	1752	1763	mirtazapine	Chemical	MESH:D000078785
31084994	2018	2029	mirtazapine	Chemical	MESH:D000078785
31084994	2060	2070	depression	Disease	MESH:D003866
31084994	2074	2082	dementia	Disease	MESH:D003704
31084994	2235	2245	depression	Disease	MESH:D003866
31084994	2249	2257	dementia	Disease	MESH:D003704
31084994	Comparison	MESH:D000078785	MESH:D020280
31084994	Negative_Correlation	MESH:D020280	MESH:D003704
31084994	Negative_Correlation	MESH:D020280	MESH:C538175
31084994	Negative_Correlation	MESH:D000078785	MESH:D000544
31084994	Negative_Correlation	MESH:D020280	MESH:D000544
31084994	Negative_Correlation	MESH:D000078785	MESH:D003866
31084994	Negative_Correlation	MESH:D020280	MESH:D003866
31084994	Negative_Correlation	MESH:D000078785	MESH:D003704
31084994	Negative_Correlation	MESH:D000078785	MESH:C538175

